February 17, 2026
Nano Holdings, Inc.
Atsushi Matsumura, Chairman, President & CEO
(4571 Tokyo Stock Exchange Growth Market)
URL: https://www.nano-hd.com/en

Neil W. Gibson Appointed as Chairman of Nano Holdings US, LLC

We are pleased to announce that Dr. Neil W. Gibson has been appointed Chairman of Nano Holdings US, LLC, our U.S. subsidiary. As a strategic investment company, NANO Holdings is committed to accelerating the growth of emerging healthcare ventures. Maximizing the potential of Japanese healthcare companies in global markets is a core pillar of our strategy and an important step in expanding the NANO Group's value-creation model worldwide.

With Dr. Gibson's appointment, we expect to significantly strengthen our investment and commercialization capabilities, enabling us to more effectively bridge Japan-originated drug discovery technologies to global markets.

Dr. Gibson is a leading drug discovery scientist who has contributed to the successful development of several major oncology therapies still widely used today, including Temodar®, Nexavar®, Tarceva®, and Xalkori®※. He is deeply knowledgeable in cutting-edge global science and development strategies. His proven track record and expertise will play an important role in enhancing the global competitiveness of Japanese healthcare companies and supporting the success of NANO and its portfolio companies.



Neil W. Gibson, Ph.D. – Biography

Dr. Gibson is a highly accomplished drug discovery scientist with over 30 years of experience and a proven record in bringing four oncology drugs to market. He is also an entrepreneur who has founded and led multiple biotech ventures to success, and he has held senior leadership roles at major pharmaceutical companies, including Pfizer and Bayer.

※ **Temodar® (temozolomide)**
A standard-of-care treatment for brain tumors, with an estimated global market size of USD 0.9 billion in 2026.
Source: Business Research Insights – Temozolomide Market (2026)

Nexavar® (sorafenib)
A molecular targeted therapy for liver and kidney cancers; Bayer reported USD 854 million in global sales in 2019.
Source: PharmaCompass – Bayer Annual Sales

Tarceva® (erlotinib)
A widely used EGFR inhibitor for lung cancer; global sales peaked at USD 1.9 billion in 2013.
Source: Anqing Chico Pharmaceutical – Global Tarceva Sales

Xalkori® (crizotinib)
A first-in-class EML4/ALK inhibitor for lung cancer, recording USD 524 million in global sales in 2023.
Source: Anqing Chico Pharmaceutical – Xalkori Market Performance